HIGH-RISK CANCER

This early-stage study tests a vaccine designed to train the immune system to attack cells with a mutated KRAS gene, which is common in pancreatic cancer. The vaccine is given to people at high risk due to family history or pancreatic cysts. The main goals are to see if the vacci…

This phase 2 trial tests a powerful mix of short-course radiation, chemotherapy (mFOLFOX6), an immunotherapy (PD-1 antibody), and a targeted drug (cetuximab or bevacizumab, depending on genetic markers) in people with high-risk rectal cancer that is mismatch repair proficient (pM…

This Phase 3 trial tests whether adding immunotherapy and a targeted drug to short-course radiotherapy and chemotherapy improves outcomes for people with high-risk rectal cancer. About 204 participants will receive either the standard treatment or the intensified combo. The study…

This phase 3 trial tests whether adding toripalimab (an immunotherapy) to capecitabine (a chemotherapy pill) as maintenance therapy works better than capecitabine alone for people with high-risk nasopharyngeal carcinoma. The study enrolls 264 adults aged 18-70 who have completed …

This phase 2 trial is testing whether giving the targeted drug olaparib (Lynparza) along with hormone therapy for 6 months before surgery can shrink or eliminate prostate cancer in men with high-risk disease and specific gene mutations. About 32 men will receive the treatment, th…

This study will give low-dose CT scans to over 6,600 people in Taiwan who are at high risk for lung cancer due to heavy smoking, family history, or environmental exposures like air pollution. The goal is to see how many people agree to screening and how many lung cancers are foun…

This study is enrolling 1,000 adults to track their lifestyle, family history, and health habits over time. Researchers will use questionnaires and body measurements to understand cancer risk factors. Participants found to be at high risk will be referred to a doctor for follow-u…